Return of Benefit to Society of Publicly Funded Innovations to Combat COVID-19
In response to the COVID-19 pandemic, significant public funds have been invested worldwide into the research, development, and manufacturing of pharmaceutical products to combat the novel coronavirus. Traditionally, intellectual property (IP) rights have been justified in the pharmaceutical sector...
Enregistré dans:
Auteur principal: | Helen Yu BSc, JD, PhD |
---|---|
Format: | article |
Langue: | EN |
Publié: |
SAGE Publishing
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3c325e7f15c64ba1b3d4d978dde48b92 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Measuring the COVID-19 Financial Threat to Hospital Markets
par: Anthony W. Orlando MSc, PhD, et autres
Publié: (2021) -
The Psychological Benefits of COVID-19 Vaccination
par: My Nguyen
Publié: (2021) -
Gender Differences in the Factors Associated With the Fear of COVID-19 Among Taiwanese Older People
par: Yueh-Ping Li PhD, et autres
Publié: (2021) -
The urgent need of public policies for promoting cardiovascular health in Latin-American women
par: Pamela Seron, Ph.D, et autres
Publié: (2021) -
Recent Advances on Drugs and Vaccines for COVID-19
par: Fang Peng MD, et autres
Publié: (2021)